A.M. Sikander: “We are expanding both organically and inorganically”

Unicycive is all-in on kidney care, focusing on underserved areas: CEO

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm engaged in the development of novel…

Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO

CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat…

Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO

Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies…